Abstract：Objective To analyze the safety risk of hydroxychloroquine so as to provide reference for clinical rational use of this drug. Methods The individual adverse drug reaction cases reported by WHO Vigilyze, China adverse drug reaction database, domestic literature and risk management plans of foreign regulatory agencies were analyzed. Results As of April 26, 2020, a total of 28 031 cases of hydroxychloroquine-caused ADRs were reported in the WHO Vigilyze database, 13 498 of which (48.2%) were serious ones. Clinical manifestations included skin rashes, nausea, allergic reactions, pain, joint swelling, fatigue and diarrhea. Between January 2004 and December 2019, 2 506 cases of ADRs associated with hydroxychloroquine sulfate tablets were reported to China adverse drug reaction database, 285 of which (11.4%) were serious, mainly related to skin and appendages disorders, gastrointestinal disorders, neurological disorders, vision disorders, and general disorders. The adverse reactions were mainly manifested as rashes, itching, dizziness, headache, nausea, abnormal vision, diarrhea and vomiting. Conclusion Attention should be paid to the possible adverse reactions caused by hydroxychloroquine in clinical use, such as cutaneous damage, gastrointestinal disorders, neurological disorders, visual damage and cardiovascular diseases. We should reinforce the safety monitoring of hydroxychloroquine, with special attention to such adverse reactions as cardiac toxicity, in order to promote the rational application of this medicine.
王涛, 刘继才, 逄瑜. 羟氯喹的药理学作用机制及安全性风险分析[J]. 中国药物警戒, 2020, 17(7): 385-388.
WANG Tao, LIU Jicai, PANG Yu. Pharmacologic Mechanism and Safety Risk Analysis of Hydroxychloroquine. Chinese Journal of Pharmacovigilance, 2020, 17(7): 385-388.
[1] 崔诚, 么雪婷, 涂思琪, 等. 硫酸羟氯喹的临床药理学研究进展[J]. 中国临床药理学与治疗学,2020, 25(2) : 221-226. [2] 上海市2019冠状病毒病临床救治专家组. 上海市2019冠状病毒病综合救治专家共识[J]. 中华传染病杂志, 2020, 38(3): 134-138. [3] Plantone D, Koudriavtseva T.Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review[J]. Clin Drug Investig, 2018,38(8):653-671. [4] Lafyatis R, York M, Marshak-Rothstein A.Antimalarial agents:closing the gate on toll-like receptors?[J]. Arthritis Rheum, 2006,54(10):3068-3070. [5] Mindell JA.Lysosomal acidification mechanisms[J]. Annu Rev Physiol, 2012(74):69-86. [6] Kaufmann AM, Krise JP.Lysosomal sequestration of amine-cont-aining drugs: analysis and therapeutic implications[J]. J Pharm Sci,2007, 96(4):729-746. [7] Ponticelli C, Moroni G.Hydroxychloroquine in systemic lupus erythematosus (SLE)[J]. Expert Opin Drug Saf, 2017, 16(3):411-419. [8] Furst DE.Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases[J]. Lupus, 1996, 5( suppl):S11-S15. [9] Rainsford KD, Parke AL, Clifford-Rashotte M, et al.Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases[J]. Inflammopharmacology, 2015, 23(5):231-269. [10] UMC. Uppsala Monitoring Centre[DB/OL].[2020-4-26]. https://vigilyze. who-umc.org. [11] 牛芳桥, 徐凡叶, 翟莎莎. 羟氯喹治疗系统性红斑狼疮出现药疹1例[J]. 航空航天医学杂志, 2012, 23(1): 128. [12] 王华光, 赵瑞, 刘丽宏. 硫酸羟氯喹致皮肤色素沉着1例并文献复习[J]. 临床药物治疗杂志, 2017, 15(9):77-79. [13] 霍静, 张永锋, 郑毅. 羟氯喹相关的皮肤色素沉着一例报告[J].天津医药, 2012, 40(7):752. [14] 潘祺琦, 罗璨.硫酸羟氯喹片致神经精神症状1例[J]. 中国药物警戒, 2016, 13(4):245. [15] 张建红, 朱立勤, 刘子艳. 羟氯喹致严重精神障碍1例报告并文献复习[J]. 中国新药与临床杂志, 2018, 37(3):182-184. [16] 施峰, 杜琇, 臧秀娟. 硫酸羟氯喹片治疗引起Ⅲ°AVB及文献复习[J]. 中国中西医结合肾病杂志, 2018, 19(7):632-633. [17] 赵瑞, 崔向丽, 刘丽宏. 硫酸羟氯喹片致QT间期延长综合征1例的药学监护[J]. 中国药物警戒, 2018, 15(11): 690-692. [18] 叶鸣, 张圣雨. 羟氯喹联合糖皮质激素致低蛋白血症患者急性药物性肝损伤1例[J]. 中国新药与临床杂志, 2019, 38(7):447-448. [19] 袁国龙, 徐亮, 牛林,等. 大剂量羟氯喹治疗系统性红斑狼疮并发难治性血小板减少1例[J]. 安徽医药, 2019, 23(11):2291-2293. [20] 王宇, 田梅. 系统性红斑狼疮伴视网膜脊髓谱系疾病服用羟氯喹发生黄斑病变一例[J]. 海南医学, 2020, 31(1): 132-134. [21] 王雪, 王曼, 姚丽艳, 等. 1例硫酸羟氯喹致老年女性面部红肿的不良反应报道[J]. 临床药物治疗杂志, 2017, 15(10):74-76. [22] FDA. Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication - FDA Cautions Against Use Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems[EB/OL]. (2020-04-24) [2020-05-08]. https://www.fda.gov/safety/ medical-product-safety-information/hydroxychloro-quine-or-chloroquine-covid-19-drug-safety-communication-fda-cautions-against-use. [23] EMA. COVID-19: reminder of risk of serious side effects with chloroquine and hydroxychloroquine[EB/OL]. (2020-04-23) [2020-05-08].https://www.ema.europa.eu/en/ news/covid-19-reminder-risk-serious-side-effects-chloroquine-hydroxychloroquine. [24] Health Canada. Chloroquine and hydroxychloroquine can have serious side effects. These drugs should be used only under the supervision of a physician[EB/OL]. (2020-04-25) [2020-05-08]. https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72885a -eng.php. [25] Yao X, Ye F, Zhang M, et al.In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)[J]. Clin Infect Dis, 2020. [Epub ahead of print]doi: 10.1093/cid/ciaa237. [26] 王涛, 刘松东, 王丹. 注射用赖氨匹林安全性风险分析及思考[J].中国药物警戒, 2019, 16(5): 281-284.
2020, Vol. 17 
